#	Pagina
attuale pagina	/open-h2020/projects/225600/index.html

Opendata, web and dolomites

Kerefish SIGNED

KerecisTM Omega3 Wound: the first fish skin substitute in the European Market for chronic wound care

Total Cost €

EC-Contrib. €

Partnership

Views

Kerefish project word cloud

Explore the words cloud of the Kerefish project. It provides you a very rough idea of what is the project "Kerefish" about.

introduce efficacy prevention trial disruptive effectiveness quality approval grafts fda global public care ce health tissue made commercialization seriously association life dressings omega3 none mark structure wound healing ebitda reimbursement atlantic dfu north countries patients treatment allderma diabetic suffering standard trials 70m wounds lately received foot disease omega content carry cod yearly chronic first skin kerecistm teamed ulcers amputation specialists efforts distributors leads moist sponsoring alone market accumulate 5 clinical sweden severe 1bn france kerecis substitute options italy 18m mammalian iceland ceritd societies revenues population kerefish solid fatty reimbursed diabetes pressing prepare endospin acids

Project "Kerefish" data sheet

The following table provides information about the project.

Coordinator	KERECIS HF. Organization address address: EYRARGATA 2 city: ISAFJORDUR postcode: 400 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Iceland [IS]
Total cost	3˙741˙044 €
EC max contribution	2˙995˙417 € (80%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-EIC-FTI-2018-2020
Funding Scheme	IA
Starting year	2019
Duration (year-month-day)	from 2019-11-01 to 2022-04-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	KERECIS HF. KERECIS HF. Organization address address: EYRARGATA 2 city: ISAFJORDUR postcode: 400 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IS (ISAFJORDUR)	coordinator	934˙159.00
2	ASS CENTRE D ETUDES ET DE RECHERCHES POUR L INTENSIFICATION DU TRAITEMENT DU DIABETE ASS CENTRE D ETUDES ET DE RECHERCHES POUR L INTENSIFICATION DU TRAITEMENT DU DIABETE Organization address address: BIOPARC GENOPOLE CAMPUS 3 BAT 5 1 RUE PIERRE FONT city: EVRY postcode: 91058 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (EVRY)	participant	1˙255˙621.00
3	ENDOSPIN ITALIA SRL ENDOSPIN ITALIA SRL Organization address address: VIA LA NEBBIA, 72 city: ROMA postcode: 168 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROMA)	participant	516˙110.00
4	ALLDERMA AB ALLDERMA AB Organization address address: HALLINGSJOVAGEN 15 city: HALLINGSJO postcode: 438 96 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (HALLINGSJO)	participant	289˙525.00

Map

Project objective

Chronic wounds in general and diabetic foot ulcers (DFU) in particular are a challenge to wound care specialists and health care systems. With 8.5% of the global population suffering from diabetes, diabetic foot disease results in costs of about €4.1bn yearly in Europe alone. Patients find their quality of life seriously affected and, in many cases, DFU leads to amputation. Standard treatment for chronic wounds today is moist wound healing with standard wound dressings. Lately, efforts have been made to introduce novel, advanced treatment options, such as skin grafts from mammalian tissue and growth factors. However, none of these has been able to provide solid evidence for clinical efficacy and cost-effectiveness, and they are not available through public health care systems in Europe. Kerecis (Iceland), the coordinator of the Kerefish project, has developed KerecisTM Omega3 Wound, a novel skin substitute derived from North Atlantic cod skin. The unique structure of the grafts and their high content of Omega 3 fatty acids promote wound healing, even in severe DFU cases. KerecisTM Omega3 Wound has received the CE mark and FDA approval. However, as it is currently not reimbursed by public health systems in Europe, it is not yet available for the European population. Kerecis has teamed up with CERITD (France), an association for diabetes prevention and treatment, Allderma (Sweden) and Endospin (Italy), two distributors of wound care products with experience in clinical trial sponsoring, to carry out large-scale clinical trials in 4 European countries and prepare the path to reimbursement and to the European health care market for this disruptive product, which will improve patients quality of life and help solve one of the pressing health problems of today’s societies. The Kerefish project will accumulate €70M of revenues and €18M of EBITDA in the first 5 years of commercialization.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "KEREFISH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "KEREFISH" are provided by the European Opendata Portal: CORDIS opendata.